Figure 1
From: Clinical trials in severe sepsis with drotrecogin alfa (activated)
Kaplan-Meier survival curves. Comparison of ENHANCE (Extended Evaluation of Recombinant Human Activated Protein C) 28-day survival with that of PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis). DrotAA, drotecogin alfa (activated). Reproduced with permission from Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266–2277.